The online version of this article (doi:10.1186/1475-2840-11-55) contains supplementary material, which is available to authorized users.
Dong-Sik Cho, Sookyoung Woo contributed equally to this work.
All authors have no relevant conflicts of interests.
K-CS; study concept and design, acquisition of data; analysis and interpretation of data. D-SC; critical revision of the manuscript for important intellectual content. J-HK; critical revision of the manuscript for important intellectual content. SW; acquisition of data; analysis and interpretation of data. SK; acquisition of data; analysis and interpretation of data. CDB; critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.
Increased low-density lipoprotein cholesterol (LDL) concentration is associated with increased risk of coronary heart disease (CHD) but a substantial risk of cardiovascular disease often remains after LDL concentrations have been treated to target. Apolipoprotein B (apo B) is the major apolipoprotein contained within atherogenic lipoproteins such as LDL, and apo B is a more reliable indicator of cardiovascular risk than LDL concentration.
Our aim was to develop a formula for calculating apo B using lipid biochemistry measurements that are commonly available in clinical practice. We examined the clinical and laboratory data from 73,047 Koreans who underwent a medical health check that included apolipoprotein B concentration. The study sample was randomly divided into a training set for prediction model building and a validation set of equal size. Multivariable linear regression analysis was used to develop a prediction model equation for estimating apo B and to validate the developed model.
The best results for estimating apo B were derived from an equation utilising LDL and triglyceride (TG) concentrations [ApoB = −33.12 + 0.675*LDL + 11.95*ln(tg)]. This equation predicted the apo B result with a concordance correlation coefficient (CCC and 95%CIs) = 0.936 (0.935,0.937)).
Our equation for predicting apo B concentrations from routine analytical lipid biochemistry provides a simple method for obtaining precise information about an important cardiovascular risk marker.
Authors’ original file for figure 112933_2012_512_MOESM1_ESM.gif
Gordon T, Kannel WB, Castelli WP, Dawber TR: Lipoproteins cardiovascular disease and death. The Framingham study. Archives Internal Med. 1981, 141: 1128-1131. 10.1001/archinte.1981.00340090024008. CrossRef
Assmann G, Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. The Am J Cardiology. 1992, 70: 733-737. 10.1016/0002-9149(92)90550-I. CrossRef
Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA : J Am Med Assoc. 1993, 269: 3015-3023. CrossRef
Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, et al: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003, 26: 2713-2721. 10.2337/diacare.26.10.2713. CrossRefPubMed
International Taskforce for Prevention of Coronary Heart Disease: Prevention of coronary heart disease: scientific background and clinical guidelines. Nutr Metab Cardiovasc Dis. 1992, 2: 113-156.
Haffner SM: Dyslipidemia management in adults with diabetes. Diabetes Care. 2004, 27 (Suppl 1): S68-S71. PubMed
Cho YK, Hur SH, Han CD, Park HS, Yoon HJ, Kim H, Nam CW, Kim YN, Kim KB, Park NH, Park HJ: Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk. Korean Circ J. 2011, 41 (3): 149-153. 10.4070/kcj.2011.41.3.149. PubMedCentralCrossRefPubMed
Choi SJ, Park SH, Lee KS, HY Park: The prevalence, awareness and treatment of high low density lipoprotein-cholesterol in korean adults without coronary heart diseases - the third Korea national health and nutrition examination survey, 2005 -.Korean. Circ J. 2012, 42 (2): 86-94.
National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002, 106: 3143-3421.
Li, et al: Serum Non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality study. Cardiovasc Diabetol. 2011, 10: 46-10.1186/1475-2840-10-46. PubMedCentralCrossRefPubMed
Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR: Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009, 55: 407-419. 10.1373/clinchem.2008.118356. CrossRefPubMed
Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, et al: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Internal Med. 2006, 259: 247-258. 10.1111/j.1365-2796.2006.01616.x. CrossRefPubMed
Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL: Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008, 51: 1512-1524. 10.1016/j.jacc.2008.02.034. CrossRefPubMed
Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, et al: Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem. 2009, 55: 473-480. 10.1373/clinchem.2008.111401. CrossRefPubMed
Kim HK, Chang SA, Choi EK, Kim YJ, Kim HS, Sohn DW, Oh BH, Lee MM, Park YB, Choi YS: Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population. Int J Cardiol. 2005, 101: 435-440. 10.1016/j.ijcard.2004.03.057. CrossRefPubMed
Genest J, Frohlich J, Fodor G, McPherson R: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ : Canadian Med Assoc J = Journal de l'Association Medicale canadienne. 2003, 169: 921-924.
Williams K, Sniderman AD, Sattar N, D'Agostino R, Wagenknecht LE, Haffner SM: Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2003, 108: 2312-2316. 10.1161/01.CIR.0000097113.11419.9E. CrossRefPubMed
Kulkarni K: Apo B measurement system and method. 2008, http://www.faqs.org/patents/app/20080261313, . Agents: DLA PIPER US LLP; IPC8 Class: AG01N3392FI; USPC Class: 436 52.
Chen Z, Strack AM, Stefanni AC, Chen Y, Wu W, Pan Y, Urosevic-Price O, Wang L, McLaughlin T, Geoghagen N, Lassman ME, Roddy TP, Wong KK, Hubbard BK, Flattery AM: Validation of human ApoB and ApoAI immunoturbidity assays for non-human primate dyslipidemia and atherosclerosis research. J Cardiovasc Transl Res. 2011, 4: 373-383. 10.1007/s12265-011-9264-4. CrossRefPubMed
- Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults
Christopher D Byrne
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II